Alyeska Investment Group
THRD

Alyeska Investment Group’s Third Harmonic Bio THRD Stock Holding History

Alyeska Investment Group’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75,000
Closed -$1.42M – 511
2022
Q3 		$1.42M Buy
+75,000
New +$1.35M 0.02% 337

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's THRD Position: Q4 2022 in Review

Alyeska Investment Group sold out of Third Harmonic Bio (THRD) in Q4 2022, closing a stake of 75,000 shares — an estimated $1.42M sold.

Alyeska Investment Group first reported a position in THRD in Q3 2022 and held it in 1 quarter. The position peaked at $1.42M in Q3 2022. 50 funds tracked by Wall St. Rank hold THRD as of Q4 2022.

  • Alyeska Investment Group reported no remaining Third Harmonic Bio position as of Q4 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 75,000 Third Harmonic Bio shares in Q4 2022, an estimated $1.42M.
  • Alyeska Investment Group first reported a position in Third Harmonic Bio in Q3 2022 and held it in 1 quarter.
  • Alyeska Investment Group's Third Harmonic Bio position peaked at $1.42M in Q3 2022.
  • 50 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2022.

Based on Alyeska Investment Group's 13F filing for Q4 2022, filed 14 Feb 2023.